References
- Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet 1997; 33: 103–121
- Bressler R. Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs. Geriatrics 2006; 61: 12–18
- DeVane CL, Liston HL, Markowitz JS. Clinical pharmacokinetics of sertraline. Clin Pharmacokinet 2002; 41: 1247–1266
- Genser D. Food and drug interaction: consequences for the nutrition/health status. Ann Nutr Metab 2008; 52(Suppl 1)29–32
- Greenblatt DJ, Patki KC, von Moltke LL, Shader RI. Drug interactions with grapefruit juice: an update (Editorial). J Clin Psychopharmacol 2001; 21: 357–359
- Hori H, Yoshimura R, Ueda N, Eto S, Shinkai K, Sakata S, et al. Grapefruit juice – fluvoxamine interaction. Is it risky or not?. J Clin Psychopharmacol 2003; 23: 422–424
- Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther 1995; 58: 127–131
- Kamijima K, Burt T, Cohen G, Arano I, Hamasaki T. A placebo-controlled, randomized withdrawal study of sertraline for major depressive disorder in Japan. Int Clin Psychopharmacol 2006; 21: 1–9
- Kane GC, Lipsky JJ. Drug-grapefruit juice interactions. Mayo Clin Proc 2000; 75: 933–942
- Kiani J, Imam SZ. Medicinal importance of grapefruit juice and its interaction with various drugs. Nutr J 2007; 6: 33
- Kupferschmidt HH, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 1995; 58: 20–28
- Lee AJ, Chan WK, Harralson AF, Buffum J, Bui BCC. The effects of grapefruit juice on sertraline metabolism: an in vitro and in vivo study. Clin Ther 1999; 21: 1890–1899
- Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair CH, Fortlaqe LA, et al. Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A4 protein expression. J Clin Invest 1997; 99: 2545–2553
- Lundmark J, Reis M, Bengtsson F. Therapeutic drug monitoring of sertraline: variability factors as displayed in a clinical setting. Ther Drug Monit 2000; 22: 446–454
- Mandrioli R, Saracino MA, Ferrari S, Berardi D, Kenndler E, Raqqi MA. HPLC analysis of the second-generation antidepressant sertraline and its main metabolite N-desmethylsertraline in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2006; 836: 116–119
- Mauri MC, Fiorentini A, Cerveri G, Volonteri LS, Regispani F, Malvini L, et al. Long-term efficacy and therapeutic drug monitoring of sertraline in major depression. Hum Psychopharmacol 2003; 18: 385–388
- Nowack R. Review article: cytochrome P450 enzyme, and transport protein mediated herb-drug interactions in renal transplant patients: grapefruit juice, St John's Wort – and beyond!. Nephrology 2008; 13: 337–347
- Obach RS, Cox LM, Tremaine LM. Sertralineis metabolized by multiple cytochrome P450 enzymes, monoamine oxidases, and glucuronyl transferases in human: an in vitro study. Drug Metab Dispos 2005; 33: 262–270
- Ohishi M, Kamijima K. A comparison of characteristics of depressed patients and efficacy of sertraline and amitriptyline between Japan and the West. J Affect Disord 2002; 70: 165–173
- Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors. An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32(Suppl 1)1–21
- Sprouse J, Clarke T, Reynolds L, Hevm J, Rollema H. Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology 1996; 14: 225–231
- Wang JH, Liu ZQ, Wang W, Chen XP, Shu Y, He N, et al. Pharmacokinetics of sertraline in relation to genetic polymorphism of CYP2C19. Clin Pharmacol Ther 2001; 70: 42–47